Peter Soparkar is CLO at Adverum Biotechnologies, Inc. (ADVM). They have made 7 open-market trades across 1 company since 2020, most recently 2025-12-09.
CIK 0001736315
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $384K since 2020, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADVM | 157,333 | $686K |
Shares reported on the most recent Form 4, priced at the 2025-12-10 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADVM | BUY | 2025-12-05 | 2025-12-08 | $4.22 | $211K | N/A | N/A | N/A |
| ADVM | SELL | 2025-05-15 | 2025-05-16 | $2.00 | $6K | +9.7% | +19.9% | +34.5% |
| ADVM | SELL | 2023-03-15 | 2023-03-17 | $0.78 | $10K | -2.7% | +14.1% | +89.4% |
| ADVM | SELL | 2022-09-19 | 2022-09-21 | $1.07 | $14K | -3.8% | -15.4% | -44.9% |
| ADVM | BUY | 2022-04-19 | 2022-04-20 | $1.14 | $25K | -5.1% | -26.9% | +46.2% |
| ADVM | BUY | 2021-12-08 | 2021-12-10 | $1.91 | $48K | -0.5% | -11.8% | -28.5% |
| ADVM | BUY | 2020-08-17 | 2020-08-19 | $13.00 | $100K | -9.2% | -7.9% | -9.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.